

CEPI Centralized Laboratory Network for COVID-19 Vaccine Testing

Why

- To facilitate rapid evaluation, approval, and dissemination of the most effective vaccine candidates
- To standardize immunological testing of Covid-19 vaccines

CEPI

Who

Qualified assays:

- Full length S,RBD, N ELISA
- IFN- γ , IL-5 ELISPOT
- Pseudo virus and wild type virus neutralization assays

What

All COVID-19 vaccine developers are invited to apply to use the Network for samples from preclinical up to clinical Phase IIa studies

Nexelis (Canada) and PHE (UK), Q2 Solutions (US), NIBSC (UK), VisMederi Srl (Italy), Viroclinics-DDL (The Netherlands), icddr,b (Bangladesh), and THSTI (India)

Where

When

From October 2020

[Press release](#)

The testing service is free of charge, except for the shipment costs

To check your eligibility, complete the [Sample Analysis Request Form](#)

How

For more information: centralizedlab@cepi.net